<DOC>
	<DOCNO>NCT01268124</DOCNO>
	<brief_summary>This phase 1 , randomize ( process use decide whether take study drug placebo study ) , inpatient study ass safety tolerability HTC-867 healthy male Japanese subject .</brief_summary>
	<brief_title>Study Evaluating The Safety Tolerability HTC-867 Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Inclusion : 1 . Men age 20 45 year inclusive screening . Sexually active men must agree use medically acceptable form contraception study continue 12 week test article administration . 2 . Body mass index ( BMI ) range 17.6 26.4 kg/m2 body weight ≥45 kg . BMI calculate take subject 's weight , kilogram , divide square subject 's height , meter , screening : BMI = Weight ( kg ) / [ Height ( ) ] 2 . 3 . Healthy determine investigator basis screen evaluation . 4 . Nonsmoker smoker few 10 cigarette per day determine history . Must able abstain smoking inpatient stay . 5 . Have high probability compliance completion study . Medical History 1 . Presence history disorder may prevent successful completion study . 2 . Any unstable medical condition . 3 . History seizure . 4 . History cardiac disorder ( hypertension ) include limited valvular disease , congestive heart failure , angina pectoris , myocardial infarction , arrhythmia . 5 . Any significant cardiovascular disease , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . 6 . Any surgical medical condition may interfere absorption , distribution , metabolism , excretion test article ( eg , resection liver , kidney , gallbladder , gastrointestinal tract ) . 7 . Acute disease state ( eg , nausea , vomit , infection , fever , diarrhea ) within 7 day study day 1 ) . 8 . History drug abuse within 1 year study day 1 . 9 . Admitted alcohol abuse history alcohol use may interfere subject 's ability comply protocol requirement . Physical Laboratory Findings 10 . Clinically significant electrocardiogram ( ECG ) abnormality . 11 . Any clinically important deviation normal limit physical examination finding , vital sign measurement , 12lead ECGs , clinical laboratory test result . 12 . Positive serologic finding human immunodeficiency virus ( HIV ) antigen antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . 13 . Positive finding urine drug screen ( eg , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates , phencyclidine [ PCP ] ) . 14 . Troponin T CKMB level reference range screening . Allergies Adverse Drug Reactions 15 . History clinically important drug allergy ( eg , relapse dermatitis , drug hypersensitivity , drug allergy , hypersensitivity ingredient test article , angioedema ) . Prohibited Treatments 16 . Use investigational drug within 90 day study day 1 prescription drug within 30 day study day 1 . 17 . Tobacco use consumption caffeinecontaining product ( eg , coffee , tea , chocolate , carbonate beverage ) alcoholic beverage within 72 hour study day 1 end inpatient confinement period . 18 . Consumption grapefruit grapefruitcontaining product within 72 hour study day 1 end inpatient confinement period . 19 . Use overthecounter drug , include herbal supplement ( except occasional use vitamin ≤100 % recommended daily allowance ) , within 14 day study day 1 ( St. John wort prohibit within 30 day study day 1 ) . 20 . Donation blood within 90 day study day 1 . Others 21 . Subjects deem investigator inappropriate accord inclusion criterion study accord screen examination .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Japanese</keyword>
</DOC>